As studies in sepsis have indicated the TREM-1 pathway as a potential therapeutic target [11–13], it is tempting to speculate that, like anti-IL-6R therapy, a beneficial effect of TREM-1 modulation in patients with COVID-19 could be also present. The gene discussed is TREM1; the disease is COVID-19.